Covalent organic frameworks (COFs) provide a tunable platform for water electrolysis. However, it is difficult to perform explicitly structural characterization for COFs due to the uncontrollable polymerization via the solvothermal method, which hinders the clear-cut exploration of the COFs' structureperformance relationship in further applications. Here, the well-defined conjugated reticular oligomers ( CROs) are designed for the first time using an aqueous micellar strategy. The CROs have definite chemical structure and can be regarded as conjugated oligomers or defect-free COFs segment. Using CROs and conducting polymer, three "muscle"-biomimetic electrocatalysts are engineered for splitting water to H 2 and O 2 . The self-assembled "muscle"like structures guarantee fully exposed active sites, fast electron conduction and mass transfer (H 2 O/H 2 /O 2 ). The "muscle"-biomimetic poly(3,4-ethylenedioxythiophene) (PEDOT)/CROs-Ru exhibit superior electrochemical performance than the COFs-Ru. In particular, the mass activity and turnover frequency (TOF) value of PEDOT/CRO OH -8-Ru are ≈95 and 38 times that of the counterpart bulk Py-COF OH . The theoretical calculation and the experimental results demonstrate that the CROs endow the electrocatalyst with an electron-rich surface and enhance carrier mobility. The enhanced water electrolysis activity of CROs-Ru can be attributed to the Schottky heterojunction suppressing the electron backflow, which facilitates the adsorption of hydrogen protons and hydroxides.

No abstract

Lung cancer patients with high programmed cell death-ligand 1 (PD-L1) expression in tumor cells and epidermal growth factor receptor (EGFR) mutations are rare, but there is no clinical standard for which treatment such patients should receive. Here, we report a 52-year-old male smoker who was diagnosed with stage IIIB lung adenocarcinoma. A rare EGFR G719A mutation was detected in the lymph node samples by next-generation sequencing (NGS), and a high PD-L1 expression was found by immunohistochemistry (IHC). After 10 cycles of induction therapy (toripalimab plus pemetrexed plus nedaplatin plus apatinib), surgery was successfully performed, followed by 2 cycles of consolidation therapy (toripalimab plus pemetrexed) and 4 cycles of maintenance therapy (toripalimab). A progression-free survival (PFS) of 7 months was achieved. In this case, we showed that the programmed cell death protein 1 (PD-1) inhibitor toripalimab plus chemotherapy and apatinib was effective and tolerable in a locally advanced EGFR-mutant non-small cell lung cancer (NSCLC) patient with a positive PD-L1 expression.

C22H28O2, orthorhombic, Pna21 (No. 33), a = 12.0841(9) Å, b = 16.6946(12) Å, c = 9.3837(8) Å, β = 90°, V = 1893.1(3) Å3, Z = 4, R gt (F) = 0.0497, wR ref (F 2) = 0.1057, T = 220 K.